Comparative study between topical hydroquinone 4% alone versus its combination with intradermal autologous platelet-rich plasma in the treatment of melasma: a split-face controlled trial

Phase 4

Recruiting

• Conditions: Melasma; melasma, autologous platelet-rich plasma, hydroquinone

• Registration Number: TCTR20210925002
• Lead Sponsor: Institute of Dermatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-25
• Study Completion: 2021-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Otherwise healthy volunteers with Fitzpatrick skin type 2, 3, 4 who have melasma on both sides of cheeks, symmetrical or nearly symmetrical

Exclusion Criteria

Individuals who tend to develop keloid/acne or having active infection such as herpes, HIV, hepatitis, on oral isotretinoin or hormonal therapy within 6 months prior to this study, has a history of bleaching/whitening agents/laser therapy/botulinum toxin injection within 6 months or filler injection within 2 years prior to this study, pregnancy, lactation, smoking, bleeding tendency, facial dermatitis, skin malignancy or other skin conditions which might affect study results, on oral or topical antioxidants including vitamin C and whitening agents and those who has more than 3 hours of sun exposure per day.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy 2,4,6,8,12,16 weeks Biophysical properties of the skin, Clinical photographs

Secondary Outcome Measures

Name	Time	Method
Safety 2,4,6,8,12,16 weeks Patient satisfaction questionaire